TerminatedPHASE1, PHASE2NCT02898753

VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease

Studying Glycogen storage disease due to acid maltase deficiency

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Valerion Therapeutics, LLC
Principal Investigator
Hal Landy, MD
Valerion Therapeutics, LLC
Intervention
VAL-1221(drug)
Enrollment
12 enrolled
Eligibility
18 years · All sexes
Timeline
20172020

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02898753 on ClinicalTrials.gov

Other trials for Glycogen storage disease due to acid maltase deficiency

Additional recruiting or active studies for the same condition.

See all trials for Glycogen storage disease due to acid maltase deficiency

← Back to all trials